《ScienceDaily,2月11日,Exercise post-vaccine bumps up antibodies, new study finds》

  • 来源专题:COVID-19科研动态监测
  • 编译者: YUTING
  • 发布时间:2022-02-21
  • Researchers at Iowa State University found 90 minutes of mild- to moderate-intensity exercise directly after a flu or COVID-19 vaccine may provide an extra immune boost.

    In the newly published study, participants who cycled on a stationary bike or took a brisk walk for an hour-and-a-half after getting a jab produced more antibodies in the following four weeks compared to participants who sat or continued with their daily routine post-immunization. The researchers found similar results when they ran an experiment with mice and treadmills.

    Antibodies are essentially the body's "search and destroy" line of defense against viruses, bacteria, fungi and parasites. Vaccines help the immune system learn how to identify something foreign and respond by bolstering the body's defenses, including an increase in antibodies.

    "Our preliminary results are the first to demonstrate a specific amount of time can enhance the body's antibody response to the Pfizer-BioNtech COVID-19 vaccine and two vaccines for influenza," said Kinesiology Professor Marian Kohut, lead author of the paper published in the journal Brain, Behavior, and Immunity.

    The researchers said the study's findings could directly benefit people with a range of fitness levels. Nearly half of the participants in the experiment had a BMI in the overweight or obese category. During 90 minutes of exercise, they focused on maintaining a pace that kept their heart rate around 120-140 beats per minute rather than distance.

    In the study, the researchers also tested whether participants could get the same bump in antibodies with just 45-minutes of exercising. They found the shorter workout did not increase the participants' antibody levels. Kohut said the research team may test whether 60 minutes is enough to generate a response in a follow-up study.

    Why the boost?

    As to why prolonged, mild- to moderate-intensity exercise could improve the body's immune response, Kohut said there may be multiple reasons. Working out increases blood and lymph flow, which helps circulate immune cells. As these cells move around the body, they're more likely to detect something that's foreign.

    Data from the mouse experiment also suggested a type of protein (i.e., interferon alpha) produced during exercise helps generate virus-specific antibodies and T- cells.

    "But a lot more research is needed to answer the why and how. There are so many changes that take place when we exercise -- metabolic, biochemical, neuroendocrine, circulatory. So, there's probably a combination of factors that contribute to the antibody response we found in our study," said Kohut.

    The researchers are continuing to track the antibody response in the participants six months post-immunization and have launched another study that focuses on exercise's effects on people who receive booster shots.

    Postdoctoral Researcher Tyanez Jones, Graduate Assistant Jessica Alley and Justus Hallam, a graduate student at the time of the study, co-authored the recently published paper with Marian Kohut. Kohut said the research team also received a lot of help from undergraduate students, including students from the ISU Science Bound Scholars Program.

  • 原文来源:https://www.sciencedaily.com/releases/2022/02/220211161313.htm
相关报告
  • 《Sciencedaily,2月17日,Study strengthens case that vitamins cannot treat COVID-19》

    • 来源专题:COVID-19科研动态监测
    • 编译者:YUTING
    • 发布时间:2022-03-02
    • A new review of COVID-19 hospitalization data by researchers at The University of Toledo has found that taking immune-boosting supplements such as vitamin C , vitamin D and zinc do not lessen your chance of dying from COVID-19. Early in the pandemic, healthcare providers tried a variety of micronutrients as potential therapies for the new illness. More recently, supplements have been promoted by some as an alternative to the safe and proven vaccines. However, Dr. Azizullah Beran said there's been little evidence those strategies work, despite the enduring interest in them. "A lot of people have this misconception that if you load up on zinc, vitamin D or vitamin C, it can help the clinical outcome of COVID-19," said Beran, an internal medicine resident at The University of Toledo College of Medicine and Life Sciences. "That hasn't been shown to be true." Beran is the lead author on a new paper that significantly strengthens the emerging medical consensus that micronutrient supplements are not an effective treatment for COVID-19. He and his collaborators reviewed 26 peer-reviewed studies from around the globe that included more than 5,600 hospitalized COVID-19 patients. Their analysis found no reduction in mortality for those being treated with vitamin D, vitamin C or zinc compared to patients who did not receive one of those three supplements. Their analysis did find that treatment with vitamin D may be associated with lower rates of intubation and shorter hospital stays, but the researchers say more rigorous study is needed to validate that finding. Vitamin C and zinc were not associated with shorter hospital stays or lowering the chance a patient would be put on a ventilator. While the study predominately looked at patients who were already sick and hospitalized with COVID-19 when given the supplements, researchers did analyze a smaller subset of individuals who had been taking vitamin D prior to contracting the virus. They found no significant difference in the mortality rate of that population either. The paper is published in the journal Clinical Nutrition ESPEN. "It's important for people to understand that taking a lot of these supplements does not translate into better outcomes," said Dr. Ragheb Assaly, a UToledo professor of medicine and the paper's senior author. "The other important message is that the answer to this disease is the vaccine. Micronutrient supplements will not offset the lack of vaccination or make you not need the vaccine." Researchers caution that the study shouldn't be interpreted as saying vitamin and mineral supplements are bad or should be avoided, but rather make it clear that they are not effective at preventing COVID-19 deaths. Beran and Assaly say it's possible that some COVID-19 patients who are malnourished or otherwise deficient in micronutrients may benefit from taking supplements, but that's because their bodies already lack essential nutrients -- not because vitamin D or vitamin C are effective against the virus. "What we're saying is this: If you don't medically need these supplements, don't take them thinking they're protective against COVID-19," Beran said. "They're not going to prevent you from getting it and they're not going to prevent you from dying."
  • 《Medicalxpress,11月15日,COVID patients on SSRI antidepressants are less likely to die, study finds》

    • 来源专题:COVID-19科研动态监测
    • 编译者:YUTING
    • 发布时间:2021-11-21
    • A large analysis of health records from 87 health care centers across the United States found that people taking a class of antidepressants called selective serotonin reuptake inhibitors (SSRIs), particularly fluoxetine, were significantly less likely to die of COVID-19 than a matched control group. The results add to a body of evidence indicating that SSRIs may have beneficial effects against the worst symptoms of COVID-19, although large randomized clinical trials are needed to prove this. "We can't tell if the drugs are causing these effects, but the statistical analysis is showing significant association," said Marina Sirota, Ph.D., associate professor of pediatrics and a member of the Bakar Computational Health Sciences Institute (BCHSI) at UC San Francisco. "There's power in the numbers." The UCSF-Stanford research team analyzed electronic health records from the Cerner Real World COVID-19 de-identified database, which had information from almost 500,000 patients across the U.S. This included 83,584 adult patients diagnosed with COVID-19 between January and September, 2020. Of those, 3,401 patients were prescribed SSRIs. The large size of the dataset enabled researchers to compare the outcomes of patients with COVID-19 on SSRIs to a matched set of patients with COVID-19 who were not taking them, thus teasing out the effects of age, sex, race, ethnicity, and comorbidities associated with severe COVID-19, such as diabetes and heart disease, as well as the other medications the patients were taking. The results showed that patients taking fluoxetine were 28 percent less likely to die; those taking either fluoxetine or another SSRI called fluvoxamine were 26 percent less likely to die; and the entire group of patients taking any kind of SSRI was 8 percent less likely to die than the matched patient controls. Though the effects are smaller than those found in recent clinical trials of new antivirals developed by Pfizer and Merck, the researchers said more treatment options are still needed to help bring the pandemic to an end. "The results are encouraging," said Tomiko Oskotsky, MD, a research scientist in Sirota's lab at BCHSI. "It's important to find as many options as possible for treating any condition. A particular drug or treatment may not work or be well tolerated by everyone. Data from electronic medical records allow us to quickly look into existing drugs that could be repurposed for treating COVID-19 or other conditions."